Development of modified-release tablets of zolpidem tartrate by biphasic quick/slow delivery system.
Zolpidem tartrate is a non-benzodiazepine analogue of imidazopyridine of sedative and hypnotic category. It has a short half-life with usual dosage regimen being 5 mg, two times a day, or 10 mg, once daily. The duration of action is considered too short in certain circumstances. Thus, it is desirable to lengthen the duration of action. The formulation design was implemented by preparing extended-release tablets of zolpidem tartrate using the biphasic delivery system technology, where sodium starch glycolate acts as a superdisintegrant in immediate-release part and hydroxypropyl methyl cellulose as a release retarding agent in extended-release core. Tablets were prepared by direct compression. Both the core and the coat contained the drug. The pre-compression blends were evaluated for angle of repose, bulk density, and compressibility index. The tablets were evaluated for thickness, hardness, weight variation test, friability, and in vitro release studies. No interaction was observed between zolpidem tartrate and excipients from the Fourier transform infrared spectroscopy and differential scanning calorimetry analysis. The results of all the formulations prepared were compared with reference product Stilnoct®. Optimized formulations showed release patterns that match the United States Pharmacopeia (USP) guidelines for zolpidem tartrate extended-release tablets. The mechanism of drug release was studied using different mathematical models, and the optimized formulation has shown Fickian diffusion. Accelerated stability studies were performed on the optimized formulation.
Department of Pharmaceutical Technology, Maharajah's College of Pharmacy, Vizianagaram-2, Andhra Pradesh, India, dr.anjanmahapatra@gmail.com.
Anjan Kumar
AK
Mahapatra
N H
NH
Sameeraja
P N
PN
Murthy
D002152:Calorimetry, Differential Scanning / Q000379:methods; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004058:Diffusion; D004339:Drug Compounding / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry; D006207:Half-Life; D006244:Hardness; D065347:Hypromellose Derivatives / Q000737:chemistry; D007700:Kinetics; D011725:Pyridines / Q000737:chemistry*; D017550:Spectroscopy, Fourier Transform Infrared / Q000379:methods; D013213:Starch / Q000031:analogs & derivatives / Q000737:chemistry; D013607:Tablets / Q000737:chemistry*; D000077334:Zolpidem
D003692:Delayed-Action Preparations; D005079:Excipients; D011725:Pyridines; D013607:Tablets; D065347:Hypromellose Derivatives; D000077334:Zolpidem; D013213:Starch; C048390:sodium starch glycolate